Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
May 01 2024 - 8:30AM
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical
company focused on developing innovative medicines for preserving
muscle for high quality weight loss, oncology, and viral induced
acute respiratory distress syndrome, today announced it will host a
conference call and audio webcast on Wednesday, May 8, 2024, at
8:00 a.m. ET to discuss its fiscal 2024 second quarter financial
results and to provide a business update.
The audio webcast will be accessible under the Investors page of
the Company’s website at www.verupharma.com. To join the conference
call via telephone, please dial 1-800-341-1602 (domestic) or
1-412-902-6706 (international) and ask to join the Veru Inc. call.
An archived version of the audio webcast will be available for
replay on the Company’s website for approximately three months. A
telephonic replay will be available at approximately 12:00 p.m. ET
by dialing 1-877-344-7529 (domestic) or 1-412-317-0088
(international), passcode 8861692, for one week.
About Veru Inc.Veru is a late clinical stage
biopharmaceutical company focused on developing novel medicines for
the treatment of metabolic diseases, oncology, and ARDS. The
Company’s drug development program includes two late-stage novel
small molecules, enobosarm and sabizabulin.
Enobosarm, a selective androgen receptor modulator (SARM), is
being developed for two indications: (i) Phase 2b clinical study of
enobosarm as a treatment to augment fat loss and to prevent muscle
loss in sarcopenic obese or overweight elderly patients receiving a
GLP-1 RA who are at-risk for developing muscle atrophy and muscle
weakness and (ii) subject to the availability of sufficient
funding, Phase 3 ENABLAR-2 clinical trial of enobosarm and
abemaciclib for the treatment of androgen receptor positive (AR+),
estrogen receptor positive (ER+) and human epidermal growth factor
receptor 2 negative (HER2-) metastatic breast cancer in the 2nd
line setting.
Sabizabulin, a microtubule disruptor, is being developed as a
Phase 3 clinical trial for the treatment of hospitalized patients
with viral-induced ARDS. The Company does not intend to undertake
further development of sabizabulin for the treatment of
viral-induced ARDS until we obtain funding from government grants,
pharmaceutical company partnerships, or other similar third-party
external sources.
The Company also has an FDA-approved commercial product, the FC2
Female Condom® (Internal Condom), for the dual protection against
unplanned pregnancy and sexually transmitted infections.
Forward-Looking StatementsThis press release
contains "forward-looking statements" as that term is defined in
the Private Securities Litigation Reform Act of 1995, including,
without limitation, express or implied statements related to
whether and when the planned phase 2b trial of enobosarm discussed
above will commence or produce topline data or patients will
progress into the extension study, the planned design, timing,
endpoints, patient population and patient size of such trial and
whether such trial will successfully meet any of its endpoints,
whether enobosarm will enhance weight loss or preserve muscle in,
or meet any unmet need for, obesity patients and whether it will
enhance weight loss, and whether the Company will be successful in
its transformation into a late stage biopharmaceutical company
focused on obesity and oncology. The words "anticipate," "believe,"
"could," "expect," "intend," "may," "opportunity," "plan,"
"predict," "potential," "estimate," "should," "will," "would" and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Any forward-looking statements in this
press release are based upon current plans and strategies of the
Company and reflect the Company's current assessment of the risks
and uncertainties related to its business and are made as of the
date of this press release. The Company assumes no obligation to
update any forward-looking statements contained in this press
release because of new information or future events, developments
or circumstances. Such forward-looking statements are subject to
known and unknown risks, uncertainties and assumptions, and if any
such risks or uncertainties materialize or if any of the
assumptions prove incorrect, our actual results could differ
materially from those expressed or implied by such statements.
Factors that may cause actual results to differ materially from
those contemplated by such forward-looking statements include, but
are not limited to, the risks that are detailed in the Company’s
periodic reports filed with the SEC, including the Company's Form
10-K for the year ended September 30, 2023, as amended by the Form
10-K/A.
Investor and Media Contact:Samuel FischExecutive Director,
Investor Relations and Corporate CommunicationsEmail:
veruinvestor@verupharma.com
Veru (NASDAQ:VERU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Veru (NASDAQ:VERU)
Historical Stock Chart
From Jul 2023 to Jul 2024